Author:
Jung Jae Hwan,Kim Seong Shik,Chung Hyunwoo,Hejri Amir,Prausnitz Mark R.
Funder
National Institutes of Health
Reference60 articles.
1. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—a cost-effectiveness analysis from a societal perspective;van Asten;PLoS One,2018
2. Long-term therapeutic effect in nonhuman primate eye from a single injection of anti-VEGF controlled release hydrogel;Yu;Bioeng. Transl. Med.,2019
3. Single ocular injection of a sustained-release anti-VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model;Adamson;J. Control. Release,2016
4. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab;Avery;Retina (Philadelphia, Pa.),2017
5. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab;Tyagi;Mol. Pharm.,2013
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献